Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1

Interventions

Rituximab 16Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 11fludarabine phosphate 10Cytarabine 9Methotrexate 8Vincristine 7blinatumomab 6Filgrastim 6Etoposide 6fludarabine 5Prednisone 5Mycophenolic Acid 5Lenalidomide 5Dexamethasone 5Cyclosporine 5merphos 4Whole-Body Irradiation 4Radiotherapy 4Ifosfamide 4Carboplatin 4venetoclax 3romidepsin 3prednylidene 3deltacortene 3Spinal Puncture 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Inotuzumab Ozogamicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Burkitt Lymphoma × X-Rays × Clear all
NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡